PARAMUS, N.J., March 10, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that ...
NS Pharma, a subsidiary of Nippon Shinyaku Co., announced that acceptance has been received by Capricor Therapeutics (CAPR) from the U.S. FDA ...
The Japanese group’s NS Pharma subsidiary has revealed that Viltepso (viltolarsen) missed its primary objective in the confirmatory RACER53 trial, and was unable to distinguish itself from ...
The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...
"With shares trading at an EV of just $680M at last night’s close despite $1B+ sales potential in the US alone and attractive terms with commercial partner NS Pharma, we expect the stock to ...
Along with Sarepta and NS Pharma’s exon-skipping therapies, which together cater for approximately a third of patients, Sarepta also has FDA approval for a gene therapy, Elevidys ...
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback